Ann: CardieX Files Form F-1 to Dual List on US Nasdaq Exchange, page-21

First 21 Last

Share
Profile

Follow
Sambi

34 Posts.

4

26/07/23

12:32

Post #: 68989209
Share

Originally posted by AmWatchingYou: ↑

Announcement is clearly a positive, but sadly Governance continues to disappoint.

A hugely important omission on p145 of the Form F-1 under “Related Party Transactions".

Recall on 9 February 2023, the coy announced in relation to the $4.5m placement at 30cps that :
“The placement was led by Directors, and specifically includes further support from major shareholder C2 Ventures, an entity controlled jointly by Craig Cooper (CEO) and Niall Cairns (Chairman), and Mr Jarrod White (Executive Director). The Placement participation of Directors will be subject to shareholder approval at the Company’s next annual general meeting.”

When they said they led the placement, did they really? If they signed a document requiring them to participate subject to shareholder approval, they why hasn't this been disclosed in the F-1?

Now that the share price has fallen over 40%, are they treating their participation like a free option?

Yet they are happy to disclose their intention to participate in the Convertible Notes - “C2 Ventures Pty Ltd is proposing to participate in CardieX’s convertible note facility...”

Was this omission an oversight or by design? Where are the Independent Directors?

I hope the regulators on both sides of the Pacific are watching.

Expand

huh whatever’s as long as the share price is moving north don’t worry about it

CDX Price at posting: 18.5¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 28 more messages in this thread...

First 21 Last

Add CDX (ASX) to my watchlist

(20min delay)
Last 5.5¢		Change 0.000(0.00%)		Mkt cap ! $16.17M

Open	High	Low	Value	Volume
5.5¢	5.5¢	5.5¢	$2.705K	49.17K

Buyers (Bids)

No.	Vol.	Price($)
1	150826	5.5¢

Sellers (Offers)

Price($)	Vol.	No.
5.9¢	38011	1

View Market Depth

No.	Vol.	Price($)
1	150826	0.055
3	216104	0.053
2	173076	0.052
3	330000	0.051
1	50000	0.050

Price($)	Vol.	No.
0.059	38011	1
0.060	17739	4
0.061	33080	1
0.062	83300	1
0.063	130000	1

Last trade - 13.07pm 07/10/2024 (20 minute delay)

CDX (ASX) Chart

Ann: CardieX Files Form F-1 to Dual List on US Nasdaq Exchange, page-21

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: CardieX Files Form F-1 to Dual List on US Nasdaq Exchange, page-21

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News